In October 2013 at the annual meeting of the Sarcoma Alliance through Collaboration and Research (SARC) in New York, NY, William D. Tap, M.D., Section Chief, Sarcoma Oncology at Memorial Sloan-Kettering Cancer Center and Principal Investigator of the Phase 3 trial of TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma (Study 406) provided an update on enrollment. A total of 517 patients were enrolled in mid-October as reported by Dr. Tap on October 31, 2013; a total of 620 patients are expected to be enrolled.
There are 96 centers for this trial. If half are at capacity, it would require roughly 2 new patients for each of the remaining centers to complete enrollment between now and Dec 31st.
as of jun 2013, 338 had been enrolled in the th-302 STS trial. since then, the trial, on average, has enrolled at a rate of about 59 patients per month. if current enrollment stays like this, the trial should be done enrolling this december.
You should be happy because you short stocks right ? I'm invested and so far it's been major progress. Therefore, I stay in. 7 figures mid to late 2014 for me with this nice little spec. Hardly enough to retire, but it's a start. How's McDonald's treating you Cmore ? Did you promote from fry cook to cashier yet ? :D